Encompass Health Corporation (NYSE:EHC) Shares Bought by Jennison Associates LLC

Jennison Associates LLC lifted its position in Encompass Health Corporation (NYSE:EHC - Free Report) by 40.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 791,109 shares of the company's stock after buying an additional 227,012 shares during the period. Jennison Associates LLC owned approximately 0.79% of Encompass Health worth $80,124,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Encompass Health by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company's stock worth $960,817,000 after purchasing an additional 138,196 shares in the last quarter. Invesco Ltd. lifted its stake in Encompass Health by 3.3% during the 4th quarter. Invesco Ltd. now owns 5,536,251 shares of the company's stock valued at $511,273,000 after acquiring an additional 176,135 shares during the period. Alliancebernstein L.P. lifted its stake in Encompass Health by 6.0% during the 4th quarter. Alliancebernstein L.P. now owns 2,076,869 shares of the company's stock valued at $191,799,000 after acquiring an additional 117,617 shares during the period. FMR LLC lifted its stake in Encompass Health by 0.8% during the 4th quarter. FMR LLC now owns 1,973,846 shares of the company's stock valued at $182,285,000 after acquiring an additional 15,831 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Encompass Health by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,679,774 shares of the company's stock valued at $155,176,000 after acquiring an additional 6,164 shares during the period. Hedge funds and other institutional investors own 97.25% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Royal Bank Of Canada lifted their target price on shares of Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a report on Monday, April 28th. Wall Street Zen lowered shares of Encompass Health from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Stephens raised shares of Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 target price for the company in a report on Thursday, June 5th. KeyCorp lifted their target price on shares of Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a report on Tuesday, May 27th. Finally, UBS Group upped their price objective on shares of Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a research report on Monday, April 28th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Encompass Health has a consensus rating of "Buy" and a consensus price target of $131.50.

Insider Buying and Selling at Encompass Health

In other news, CEO Mark J. Tarr sold 118,384 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the sale, the chief executive officer owned 527,070 shares of the company's stock, valued at approximately $64,054,817.10. This represents a 18.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total transaction of $498,974.19. Following the completion of the sale, the insider directly owned 11,958 shares in the company, valued at approximately $1,394,422.38. This trade represents a 26.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 132,663 shares of company stock valued at $16,034,082 over the last 90 days. 2.10% of the stock is owned by insiders.

Encompass Health Trading Down 1.4%

Shares of EHC traded down $1.57 during mid-day trading on Tuesday, reaching $108.43. The stock had a trading volume of 1,076,873 shares, compared to its average volume of 734,478. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.06 and a quick ratio of 1.06. Encompass Health Corporation has a 52-week low of $82.74 and a 52-week high of $123.13. The business's fifty day moving average is $119.05 and its 200 day moving average is $107.02. The firm has a market cap of $10.93 billion, a price-to-earnings ratio of 22.40, a P/E/G ratio of 2.23 and a beta of 0.88.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a net margin of 8.97% and a return on equity of 17.63%. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the prior year, the firm posted $1.12 earnings per share. Encompass Health's quarterly revenue was up 10.6% on a year-over-year basis. On average, sell-side analysts predict that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st were given a $0.17 dividend. The ex-dividend date was Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.63%. Encompass Health's payout ratio is currently 14.05%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.